Claudia
Caltagirone
*a,
Massimiliano
Arca
a,
Angela M.
Falchi
b,
Vito
Lippolis
a,
Valeria
Meli
a,
Maura
Monduzzi
a,
Tommy
Nylander
c,
Antonella
Rosa
b,
Judith
Schmidt
d,
Yeshayahu
Talmon
d and
Sergio
Murgia
*a
aDipartimento di Scienze Chimiche e Geologiche, Università degli Studi di Cagliari, S.S. 554 Bivio per Sestu, 09042, Monserrato, CA, Italy. E-mail: ccaltagirone@unica.it; murgias@unica.it; Tel: +39 070 675 4452
bDipartimento di Scienze Biomediche, Università di Cagliari, S.S. 554 Bivio Sestu, I-09042, Monserrato, CA, Italy
cDivision of Physical Chemistry, Department of Chemistry, Center for Chemistry and Chemical Engineering, Lund University, P.O. Box 124, SE-221 00 Lund, Sweden
dDepartment of Chemical Engineering, Technion – Israel Institute of Technology, Haifa 32000, Israel
First published on 25th February 2015
We here discuss the potential theranostic nanomedicine application of an innovative formulation consisting of monoolein-based nanoparticles with a two-dimensional hexagonal inner structure stabilized in water using a mixture of PEO132–PPO50–PEO132 block copolymers with and without conjugated folate for targeting. The proposed tumor-cell targeted formulation was shown to be able to simultaneously host the model anticancer drug camptothecin and a pyrene-modified BODIPY fluorophore, based on dynamic light scattering, small-angle X-ray scattering, and cryogenic transmission electron microscopy. The photophysical properties of the fluorophore were studied in solution in various solvents. A marked fluorescent solvatochromism, whose origin was explained by time-dependent density functional theory theoretical calculations, was observed. Fluorescence microscopy showed that HeLa cells readily internalize these nanoparticles, and that the fluorophore localizes within the lipid droplets. In addition, cytotoxicity test revealed that these nanoparticles are not toxic at the concentration used for the imaging analysis.
As for lamellar phases that can be dispersed into vesicles, the cubic and hexagonal phases can be formulated into stable colloidal dispersion in water, known as cubosomes and hexosomes, respectively. In order to obtain mono-disperse formulations, a dispersion agent like the nonionic poly(ethylene oxide)–poly(propylene oxide)–poly(ethylene oxide) (PEO–PPO–PEO) triblock copolymers, known as Pluronics, can be used.14,15 These copolymers anchor their hydrophobic moiety in the nanoparticle, while protruding their hydrophilic segments into the solvent. This provides the particles with a PEO corona, which ensures a strong steric stabilization of the nanoparticles. Recently, such dispersions were proposed as platforms in theranostic nanomedicine.16–20 With the purpose of discovering and treating diseases at the earliest stage and with limited side effects, a new strategy to engineer different kinds of nanocarriers for the sustained, controlled, and targeted delivery of both therapeutic and diagnostic agents at the same time has emerged.21 Indeed, our group has demonstrated that, as with other kinds of nanoparticles, cubosomes can be simultaneously loaded with optical imaging agents and anticancer drugs.16,19 Cubosome and hexosome formulations possess a number of properties that can be exploited in nanomedicine but, most of all, (i) they have the right size for theranostic applications, and (ii) they are biodegradable. Moreover, these nanoparticles can be considered to be stealth particles, because their PEO corona is expected to prevent the adsorption of macromolecules on the nanoparticle surface. This prevents the formation of the biomolecular corona, thus reducing the clearance from the bloodstream via the mononuclear phagocytic system (MPS).22 When considering cubosomes and hexosomes for cancer diagnostic and therapy (as in the case discussed in this paper), it deserves also noticing that their size is within the range required for the tumor tissues passive targeting through the enhanced permeation mechanism (EPR).23 We also proved that decoration of their surface with targeting moieties capable of addressing them at cancer cells is feasible, making these lipid-based nanoparticles even more appealing for theranostic nanomedicine applications in oncology.16
Over the past decade increasing efforts have been devoted to the synthesis of new organic chromophores or nanoparticles24,25 with strong absorption and emission bands for imaging applications, both in vitro and in vivo. In particular, considerable attention has been addressed towards the development of derivatives of 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) because of their high molar extinction coefficients and quantum yields, excellent photostability and high solubility in commonly used organic solvents. BODIPY derivatives have been included into different type of nanoparticles,26–33 belonging both to the hard and the soft matter realm.
Here, we report the formulation of MO-based hexosomes loaded with both the model chemotherapeutic drug camptothecin and a pyrene-modified BODIPY fluorophore (Py-BODIPY) also stabilized by a mixture of Pluronic F108 (PF108) and folate-conjugated PF108 (PF108-FA), and investigate their physicochemical and photophysical properties. Theoretical calculations were used to elucidate the origin of the peculiar fluorescent properties of Py-BODIPY and the localization of the dye inside the nanoparticles.
In particular, the BODIPY derivative containing a pyrene group (Py-BODIPY) in the meso position was reported for the first time by Peña-Cabrera and co-workers36 using the Liebeskind–Srögl cross-coupling reaction between 8-thiomethylBODIPY and pyrene boronic acid, catalyzed by copper(I) thiophene-2-carboxylate (CuTC). Herein, we succeeded in synthesizing Py-BODIPY using the classic Lindsey method,37i.e., acid-catalyzed condensation of 1-pyrenecarboxaldheide with pyrrole, followed by oxidation with DDQ and exposure to triethylamine and BF3·Et2O (Scheme 1 and ESI† for synthetic details).
Although the method reported by Peña-Cabrera avoids the synthesis of dipyrromethanes precursors which might be difficult to purify, it requires the synthesis of both 8-thiomethylBODIPY and the catalyst. The Lindsey method is more straightforward to prepare Py-BODIPY as it requires two steps, being the 1-pyrenecarboxaldheide commercially available.
Here, we studied the photophysical properties of Py-BODIPY in different solvents covering a variety of polarities larger than that previously reported,38 and ranging from apolar hexane to polar DMSO (Table 1). While the absorption spectrum of Py-BODIPY showed negligible changes in the different solvents (ESI, Fig. S1†), its emission properties were strongly dependent on the polarity of the solvent, with the maximum of the fluorescence emission ranging from 523 nm in hexane to 709 nm in DMSO (Fig. 1).
Solvent | λ exc (nm) | λ emis (nm) | Φ |
---|---|---|---|
Hexane | 504 | 523 | 0.25 |
Toluene | 507 | 582 | 0.14 |
DCM | 505 | 670 | 2.0 × 10−2 |
THF | 504 | 630 | 4.0 × 10−2 |
EtOAc | 502 | 627 | 4.3 × 10−3 |
Acetone | 502 | 662 | 8.9 × 10−3 |
DMF | 505 | 670 | 6.1 × 10−3 |
MeCN | 499 | 708 | 4.9 × 10−3 |
DMSO | 507 | 709 | 9.5 × 10−3 |
EtOH | 502 | 651 | 6.8 × 10−3 |
MeOH | 501 | 662 | 5.6 × 10−3 |
Fig. 1 Fluorescence spectra of Py-BODIPY in different solvents. [Py-BODIPY] = 2.5 × 10−5 M; λexc between 499 and 507 nm (see Table 1). |
In general, DLS results reported in Table 2 confirm that the 80/20 mixture of PF108/PF108-FA was able to stabilize the formulations as a nanometer-size particle dispersion with quite a low polydispersity and highly negative ζ-potential. Moreover, encapsulation of the fluorophore and the drug, even when they are formulated simultaneously, did not cause appreciable alterations in the size, the PDI, and the ζ-potential of the nanoparticles (Table 2).
Formulation | D av (nm) | PDI | ζ-potential (mV) |
---|---|---|---|
HexFA | 168 ± 1 | 0.20 | −33 ± 1 |
HexCFA | 170 ± 1 | 0.20 | −36 ± 1 |
HexBFA | 177 ± 1 | 0.22 | −32 ± 1 |
HexCBFA | 172 ± 1 | 0.20 | −35 ± 1 |
The inner symmetry and the stability as a function of the temperature of the HexCBFA formulation were determined by synchrotron SAXS experiments. The diffraction patterns recorded at 25, 37, and 50 °C are reported in Fig. 2. All of them are dominated by a strong reflection peak followed, at higher q values, by two weaker reflections. The positions of these three Bragg peaks, in the ratio 1:√3:2, are always consistent with that expected for a reverse hexagonal phase. With temperature increasing, the lattice parameters, a, were found to be 59(±1), 57(±1), and 55(±1) Å, respectively, while the corresponding radius of the water channels rw were 31(±1), 30(±1), and 29(±1) Å, respectively. This is as generally observed for liquid crystalline systems.39 Nonetheless, the nanoparticles retain their internal reverse hexagonal symmetry even at the highest temperature (50 °C).
Cryo-TEM observations of the same sample (Fig. 3) showed the presence of quasi-spherical nanoparticles characterized by curved striations and the absence of the small unilamellar vesicles usually found in cubosomes formulations, either attached to the nanoparticles or dispersed as single entities. Curved striations are a characterizing feature of the hexosomes,40,41 and are related to the peculiar configuration adopted by the close (hexagonally) packed and deformable water tubes that constitutes the internal nanostructure.42
Fig. 3 Cryo-TEM image of the same sample investigated in Fig. 2. |
From a photophysical point of view, when the HexCBFA formulation (dilution 1:30) was excited at 330 nm an emission band with the maximum centered at 532 nm (Fig. 4) was observed, a position quite similar to that observed for the fluorophore dissolved in hexane (λemiss = 523 nm).
Fig. 4 Emission spectra of Py-BODIPY in hexane (blue curve) (λexc = 350 nm) and of HexCBFA in water (dilution 1:30), λexc = 330. |
The photostability of the HexCBFA formulation was tested by irradiating the sample under a UV-lamp (λexc = 365 nm) for 24 h. No changes were observed in the emission properties of the formulation in these conditions.
Given the shape and the size of these spots and the apolar nature of the dye, it could be inferred that the Py-BODIPY localizes in the lipid droplets. The latter are dynamic storage organelles that represent an intracellular reservoir of neutral lipids, such as triacylglycerols and cholesteryl esters, part of the lipid metabolism and used for membrane lipid synthesis. We recently demonstrated that monoolein-based nanoparticles (cubosomes) treatment induces intracellular accumulation of neutral lipids in the cytoplasmic lipid droplets.16 To investigate whether the Py-BODIPY fluorescence is localized in the lipid droplets, HexBFA-treated cells, grown on coverslips, were fixed and labeled with LipidTOX, a red neutral lipid stain with an extremely high affinity for neutral lipid droplets. This treatment resulted in the intracellular appearance of a colocalized Py-BODIPY (green) and LipidTOX (red) fluorescence, as shown by yellow fluorescence in the merged image and by intensity fluorescence profiles (Fig. 6).
The two nanoparticle formulations, HexFA and HexBFA, were also tested for cytotoxicity (MTT assay) in HeLa cells. Fig. 7 shows the viability, expressed as % of the control, induced in HeLa cells after 4 h incubation. Evidently, treatments with both nanoparticle formulations did not induce a relevant reduction in cell viability as compared with control cells (see ESI† for Experimental details).
In agreement with what was reported previously,38 the HOMO−1 and the LUMO are π-orbitals located on the BODIPY moiety, while the HOMO is centred on the pyrenyl substituent (Fig. 9), both in the gas phase and in solution.
Fig. 9 Molecular orbital isosurfaces of HOMO−1 (a), HOMO (b), and LUMO (c) calculated for Py-BODIPY. Cutoff value 0.05 e. |
Time-Dependent (TD) DFT calculations show that the singlet electron transition at the lowest energy S0 → S1 (about 2.2 eV, Table S1 and Fig. S3, ESI†) calculated for Py-BODIPY arises entirely from a HOMO → LUMO monoelectronic excitation, corresponding to a charge transfer (CT) process between the pyrene and the indacene systems. Due to the π-nature of the molecular orbitals (Fig. 9), in order for the overlap integral between the wavefunctions of HOMO and LUMO to be different from zero, the deviation of τ (the rotation of the pyrenyl ring, see ESI† for Experimental details) from orthogonality is required. Accordingly, this transition was calculated to be forbidden when the pyrene and the indacene planes were forced to be perpendicular. As a consequence of the CT nature of the transition, the S0 → S1 transition, which shows a very low oscillator strength at the optimised geometry, is calculated to be moderately solvatochromic in character (with a variation Δλ in the calculated absorption wavelength of about 25 nm on passing from toluene to DMF).
The S0 → S2 transition (falling at about 3.0 eV, see Table S1 and Fig. S3, ESI†) is instead assigned to a HOMO−1 → LUMO excitation. Due to its non-polar character, this transition is independent of the solvent (Δλ = 5 nm). Although difference in the excitation energies between the two transitions (about 0.8 eV, see Table S1, ESI†) might be overestimated by TDDFT calculations because of their difference in polarity, the structured experimental absorption band at about 500 nm can be attributed to the convolution of the transitions leading to the S1 and S2 excited states. TDDFT calculations allow accounting for the fluorescence of Py-BODIPY. Indeed, it is conceivable that the UV excitation from S0 to a Sk excited state is followed by an internal conversion to the S2 excited state. The possibility of the pyrene group to rotate (the libration vibration is calculated at about 20 cm−1 for the ground state), shown by the PES analysis (see ESI and Fig. S2†), could be responsible for the vibrational internal conversion S2 → S1. Hence, fluorescence emission would involve the S1 → S0 radiative relaxation. From a qualitative point of view, the polar nature of S1 nicely accounts for the remarkable solvatochromism of the emission discussed above. Indeed, in polar solvents (such as DMF, alcohols, acetonitrile) the S1 singlet excited state is stabilised (E < 2.2 eV, Table S1 and Fig. S3, ESI†) by up to 0.1 eV with respect to nonpolar solvents (hexane, toluene), so that emission is expected to occur at lower energies, as found experimentally (Fig. 1). Accordingly, the fluorescent emission observed in the hexosomes, similar to that detected in hexane, reflects the non-polar nature of the environment experienced by the imaging agent (the hydrophobic MO chains), strongly supporting the localization of the Py-BODIPY within the bilayer.
Integration of therapeutics and imaging agents within a single theranostic nanoparticle allows monitoring drug delivery, release, and efficacy, contributing to realize tailor-made therapies that, besides the study of genetic variations and biomarkers, exploit the development of imaging methods for predicting and evaluating therapeutic responses.45 Therefore, results here presented encourage the use of these nanoparticles in theranostic nanomedicine for personalized diagnosis and treatment of tumors.
Footnote |
† Electronic supplementary information (ESI) available: Material and methods; synthesis of Py-BODIPY; details of DFT calculations. See DOI: 10.1039/c5ra01025j |
This journal is © The Royal Society of Chemistry 2015 |